{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:20:46Z","timestamp":1788186046852,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T00:00:00Z","timestamp":1594771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12325-020-01411-0","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T10:03:58Z","timestamp":1594807438000},"page":"4175-4189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy of Tiotropium\/Olodaterol Compared with Tiotropium as a First-Line Maintenance Treatment in Patients with COPD Who Are Na\u00efve to LAMA, LABA and ICS: Pooled Analysis of Four Clinical Trials"],"prefix":"10.1007","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01431274","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01431287","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01964352","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02006732","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Roland","family":"Buhl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"de la Hoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary T.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,15]]},"reference":[{"key":"1411_CR1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. https:\/\/goldcopd.org\/wp-content\/uploads\/2019\/11\/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed 27 Mar 2020."},{"key":"1411_CR2","first-page":"573","volume":"6","author":"DW Mapel","year":"2011","unstructured":"Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573\u201381.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"143","key":"1411_CR3","doi-asserted-by":"publisher","first-page":"160043","DOI":"10.1183\/16000617.0043-2016","volume":"26","author":"L Calzetta","year":"2017","unstructured":"Calzetta L, Rogliani P, Ora J, Puxeddu E, Cazzola M, Matera MG. LABA\/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017;26(143):160043.","journal-title":"Eur Respir Rev"},{"key":"1411_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2147\/COPD.S130482","volume":"12","author":"GJ Rodrigo","year":"2017","unstructured":"Rodrigo GJ, Price D, Anzueto A, et al. LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907\u201322.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"9","key":"1411_CR5","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1164\/rccm.202003-0625ST","volume":"201","author":"L Nici","year":"2020","unstructured":"Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56\u2013e69.","journal-title":"Am J Respir Crit Care Med"},{"key":"1411_CR6","unstructured":"American Association for Respiratory Care. Confronting COPD in America: Executive summary. 2011. https:\/\/c.aarc.org\/resources\/confronting_copd\/exesum.pdf. Accessed 27 Mar 2020."},{"issue":"1","key":"1411_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-016-0387-7","volume":"17","author":"D Singh","year":"2016","unstructured":"Singh D, Gaga M, Schmidt O, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO\u00ae studies. Respir Res. 2016;17(1):73.","journal-title":"Respir Res"},{"issue":"4","key":"1411_CR8","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2\u20134). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"issue":"10","key":"1411_CR9","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"key":"1411_CR10","doi-asserted-by":"publisher","unstructured":"Buhl R, Singh D, de la Hoz A, Xue W, Ferguson GT. Benefits of tiotropium\/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of the TONADO\u00ae and OTEMTO\u00ae studies. Adv Ther. 2020. https:\/\/doi.org\/10.1007\/s12325-020-01373-3.","DOI":"10.1007\/s12325-020-01373-3"},{"issue":"2","key":"1411_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1183\/09031936.03.00068503a","volume":"21","author":"TJ Witek","year":"2003","unstructured":"Witek TJ, Mahler DA.  Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003;21(2):267\u201372.","journal-title":"Eur Respir J"},{"issue":"3","key":"1411_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","volume":"1","author":"JA Wedzicha","year":"2013","unstructured":"Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1(3):199\u2013209.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1411_CR13","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","volume":"189","author":"PW Jones","year":"2014","unstructured":"Jones PW, Beeh KM, Chapman KR, et al. Minimal Clinically Important Differences in Pharmacological Trials. Am J Respir Crit Care Med. 2014;189(3):250\u20135.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1411_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S2213-2600(14)70038-4","volume":"2","author":"PW Jones","year":"2014","unstructured":"Jones PW. Estimation and application of the minimum clinically important difference in COPD. Lancet Respir Med. 2014;2(3):167\u20139.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1411_CR15","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","volume":"33","author":"MR Maleki-Yazdi","year":"2017","unstructured":"Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33(12):2188\u201399.","journal-title":"Adv Ther"},{"issue":"4","key":"1411_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/resp.13651","volume":"25","author":"S Muro","year":"2020","unstructured":"Muro S, Yoshisue H, Kostikas K, Olsson P, Gupta P, Wedzicha JA. Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-na\u00efve COPD patients: a pooled analysis. Respirology. 2020;25(4):393\u2013400.","journal-title":"Respirology"},{"key":"1411_CR17","first-page":"A3317","volume":"199","author":"LH Bjermer","year":"2019","unstructured":"Bjermer LH, Kerwin E, Maltais F, et al. Comparative efficacy and safety of umeclidinium\/vilanterol, umeclidinium and salmeterol in symptomatic maintenance-na\u00efve and maintenance-treated chronic obstructive pulmonary disease: a pre-specified secondary analysis of the EMAX trial. Am J Respir Crit Care Med. 2019;199:A3317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1411_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12931-017-0548-3","volume":"18","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67.","journal-title":"Respir Res"},{"key":"1411_CR19","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.2147\/COPD.S184424","volume":"13","author":"KM Johnson","year":"2018","unstructured":"Johnson KM, Safari A, Tan WC, et al. Heterogeneity in the respiratory symptoms of patients with mild-to-moderate COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3983\u201395.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"1411_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/COPD.S27480","volume":"7","author":"C Tantucci","year":"2012","unstructured":"Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:95\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1411_CR21","first-page":"277","volume":"9","author":"NG Csikesz","year":"2014","unstructured":"Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis. 2014;9:277\u201386.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"issue":"3","key":"1411_CR22","doi-asserted-by":"publisher","first-page":"1802049","DOI":"10.1183\/13993003.02049-2018","volume":"53","author":"F Maltais","year":"2019","unstructured":"Maltais F, Aumann JL, Kirsten A-M, et al. Dual bronchodilation with tiotropium\/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. Eur Respir J. 2019;53(3):1802049.","journal-title":"Eur Respir J"},{"issue":"8","key":"1411_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1164\/rccm.201706-1288OC","volume":"198","author":"T Troosters","year":"2018","unstructured":"Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021\u201332.","journal-title":"Am J Respir Crit Care Med"},{"key":"1411_CR24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2147\/COPD.S205382","volume":"14","author":"Y Sun","year":"2019","unstructured":"Sun Y, Zhou J. New insights into early intervention of chronic obstructive pulmonary disease with mild airflow limitation. Int J Chron Obstruct Pulmon Dis. 2019;14:1119\u201325.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"4","key":"1411_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/resp.13703","volume":"25","author":"D Singh","year":"2019","unstructured":"Singh D. One bronchodilator or two? Translating clinical trials into clinical practice. Respirology. 2019;25(4):352\u20133.","journal-title":"Respirology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01411-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01411-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:34:14Z","timestamp":1628613254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01411-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,15]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01411-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,15]]},"assertion":[{"value":"27 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}